Posted by Michael Wonder on 26 May 2021
Myovant Sciences and Pfizer receive FDA approval for Myfembree, the first once daily treatment for heavy menstrual bleeding associated with uterine fibroids
26 May 2021 - Myovant and Pfizer will jointly commercialise Myfembree with product availability expected in June.
Myovant Sciences and Pfizer today announced that the U.S. FDA has approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), the first once daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, with a treatment duration of up to 24 months.
